Independent Franchise Partners Adds $19M in Kenvue Inc. ($KVUE)

Key Points

  • Independent Franchise Partners changed its Kenvue Inc. ($KVUE) stake by 2.21% last quarter, boosting to 49,208,848 shares worth $892.94 million.
  • Wall Street's consensus rating on $KVUE is Hold and an average price target of $19.50.
  • $KVUE last traded around $18.15.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Independent Franchise Partners increased its position in Kenvue Inc. ($KVUE) by 2.21% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,208,848 shares of Kenvue Inc. after buying 1,062,372 shares during the quarter. Independent Franchise Partners's holdings in Kenvue Inc. were worth $892.94 million as of its most recent filing.

Kenvue Inc. Stock Down 5.3%

Shares of Kenvue Inc. ($KVUE) traded around $18.15 on Saturday, down 5.3% for the day.

Last price$18.15
Market cap$36.26B
P/E ratio22.48
Forward P/E15.21
PEG ratio1.58
Beta0.43
52-week low$14.02
52-week high$20.82
50-day MA$19.15
200-day MA$17.91
Current ratio1
Quick ratio0.61
Debt-to-equity0.82

Kenvue Inc. Earnings

EPS (ttm)$0.84
Revenue (ttm)$15.41B
Revenue growth3%
Net margin10.76%
Return on equity15.58%
Next earningsNov 5, 2026

Kenvue Inc. Dividend

Annual dividend$0.84
Dividend yield438%
Payout ratio97.65%
Ex-dividend dateAug 12, 2026

Analysts Set New Price Targets

ConsensusHold
Average target$19.50
High target$23
Low target$18
Analysts covering12

About Kenvue Inc.

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

ExchangeNYSE
SectorConsumer Defensive
IndustryHousehold & Personal Products
HeadquartersSummit, NJ
CEOMr. Kirk L. Perry
Employees21,780

Get Kenvue Inc. alerts

New 13F filings, insider trades, and analyst moves on $KVUE, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.